Australian scientists have found a natural compound in seaweed that can halt inflammation after traumatic brain injury.

Bristol-Myers is moving a new med that targets LAG-3 into late-stage testing as an add-on to Opdivo for resistant melanoma patients.

Oncolytic viruses, which have had limited success in human trials, may get a boost from a protein-inhibiting agent.

A University of Toronto team reported promising results from a trial of tiny injectable patches made from cardiac tissue.

Scientists at Yale University believe they’ve discovered how lysosomes—the "garbage disposal" units in brain cells—contribute to Alzheimer’s.

An approved diabetes drug may change the progression of Parkinson's disease rather than just treating symptoms while the disease worsens.

Feinstein Institute-led researchers used an Alzheimer’s drug to reduce inflammation in people with metabolic syndrome.

Targeting a cell process that promotes protein clumping could lead to new drugs for ALS.

A pair of experimental vaccines protected mouse fetuses from brain defects caused by Zika infection.

Anti-CRISPR proteins may be the key to preventing harmful side effects from off-target editing.

R&D